AAV9-Mediated Gene Therapy for Infantile-Onset Pompe's Disease

Area of Science:

• Medical Genetics
• Neurology
• Biotechnology

Background:

• Infantile-onset Pompe disease is a rare genetic disorder causing progressive muscle weakness.
• Current treatments are limited, highlighting the need for novel therapeutic strategies.
• Enzyme replacement therapy has shown some efficacy but faces challenges.

Purpose of the Study:

• To evaluate the safety and efficacy of adeno-associated virus serotype 9 (AAV9) gene therapy in infantile-onset Pompe disease.
• To assess cardiac and motor function improvements following AAV-GAA treatment.
• To monitor for adverse events and immune responses to the gene therapy vector.

Main Methods:

• Four patients with infantile Pompe disease received a single intravenous infusion of AAV9 vector encoding human acid α-glucosidase (GAA).
• Dose administered was 1.2 × 10^14 vector genomes per kilogram.
• Patients were monitored for 52 weeks for clinical outcomes, cardiac function, motor development, and immune responses.

Main Results:

• Three out of four patients showed improvements in cardiac outcomes and motor function over 52 weeks.
• No anti-GAA antibodies were detected in any patient during the observation period.
• Respiratory tract infections were the most frequently reported adverse events; one patient was withdrawn and died.

Conclusions:

• AAV9-mediated gene therapy is a potential treatment for infantile-onset Pompe disease, demonstrating clinical benefits.
• The treatment appears safe regarding immunogenicity, with no anti-GAA antibodies observed.
• Further research and larger trials are warranted to confirm efficacy and long-term safety.